Impact of genetic counselling strategy on diagnostic yield and workload for genome sequencing-based tumour diagnostics.

Genome Sequencing Germline cancer genetics molecular diagnostics validation

Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
22 Nov 2023
Historique:
received: 17 07 2023
revised: 17 11 2023
accepted: 19 11 2023
medline: 25 11 2023
pubmed: 25 11 2023
entrez: 25 11 2023
Statut: aheadofprint

Résumé

PurposeGenome sequencing (GS) enables comprehensive molecular analysis of tumours and identification of hereditary cancer predisposition. According to guidelines, directly determining pathogenic germline variants (PGVs) requires pre-test genetic counselling, which is cost-ineffective. Referral for genetic counselling based on tumour variants alone could miss relevant PGVs and/or result in unnecessary referrals. MethodsWe validated GS for detection of germline variants and simulated three strategies using paired tumour-normal genome sequencing data of 937 metastatic patients. In strategy-1 genetic counselling prior to tumour testing allowed direct PGV analysis. In strategy-2 and -3, germline testing and referral for post-test genetic counselling is based on tumour variants using Dutch (strategy-2) or ESMO-PMWG (strategy-3) guidelines. ResultsIn strategy-1, PGVs would be detected in 50 patients (number-needed-to counsel; NTC=18.7). In strategy-2, 86 patients would have been referred for genetic counselling and 43 would have PGVs (NTC=2). In strategy-3, 94 patients would have been referred for genetic counselling and 32 would have PGVs (NTC=2.9). Hence, 43 and 62 patients, respectively, were unnecessarily referred based on a somatic variant. ConclusionBoth post-tumour test counselling strategies (2 and 3) had significantly lower NTC, and strategy-2 had the highest PGV yield. Combining pre-tumour test mainstreaming and post-tumour test counselling may maximize the clinically relevant PGV yield and minimize unnecessary referrals.

Identifiants

pubmed: 38006283
pii: S1098-3600(23)01048-1
doi: 10.1016/j.gim.2023.101032
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101032

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Roelof Koster (R)

The Netherlands Cancer Institute, Amsterdam, The Netherlands; Equal contribution, Amsterdam, The Netherlands. Electronic address: r.koster@nki.nl.

Luuk J Schipper (LJ)

The Netherlands Cancer Institute, Amsterdam, The Netherlands; Equal contribution, Amsterdam, The Netherlands.

Noor A A Giesbertz (NAA)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Daphne van Beek (D)

Hartwig Medical Foundation, Amsterdam, The Netherlands.

Matías Mendeville (M)

Hartwig Medical Foundation, Amsterdam, The Netherlands.

Kris G Samsom (KG)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Efraim H Rosenberg (EH)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Frans B L Hogervorst (FBL)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Paul Roepman (P)

Hartwig Medical Foundation, Amsterdam, The Netherlands.

Mirjam C Boelens (MC)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Linda J W Bosch (LJW)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Jose G van den Berg (JG)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Gerrit A Meijer (GA)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Emile E Voest (EE)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Edwin Cuppen (E)

Hartwig Medical Foundation, Amsterdam, The Netherlands.

Marielle W G Ruijs (MWG)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Tom van Wezel (T)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Lizet van der Kolk (L)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Kim Monkhorst (K)

The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: k.monkhorst@nki.nl.

Classifications MeSH